Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.180
-0.270 (-7.83%)
At close: Apr 1, 2025, 4:00 PM
3.400
+0.220 (6.92%)
After-hours: Apr 1, 2025, 4:29 PM EDT
Alterity Therapeutics Revenue
Alterity Therapeutics had revenue of 1.61M AUD in the half year ending December 31, 2024, a decrease of -32.69%. This brings the company's revenue in the last twelve months to 3.72M, up 8.55% year-over-year. In the fiscal year ending June 30, 2024, Alterity Therapeutics had annual revenue of 4.02M with 2.63% growth.
Revenue (ttm)
3.72M AUD
Revenue Growth
+8.55%
P/S Ratio
14.51
Revenue / Employee
372,449 AUD
Employees
10
Market Cap
33.45M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ATHE News
- 5 days ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Raises A$40.0 million in Placement - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy - GlobeNewsWire
- 2 months ago - Appendix 4C – Q2 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - GlobeNewsWire
- 5 months ago - Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - GlobeNewsWire